News

From bargain to multi-million exit
Enlarge image

BusinessIceland

From bargain to multi-million exit

12.12.2012 - Amgen will buy deCODE Genetics for US$415m in cash. The US firm gains access to a pioneering genetics platform that has a history with steep turns.

By purchasing deCODE of Iceland, Amgen will intensify efforts to boost its drive to develop targeted drugs. Founded in 1996, deCODE Genetics specialises in analysing and understanding the links between the genome and disease susceptibility, through using its access to a well-defined population in Iceland. The company has discovered genetic risk factors for a number of diseases ranging from cardiovascular illnesses to cancer. However, deCODE failed to fulfill early expectations after going public in 2000. In 2009, the biotech filed for bankruptcy protection, loaded with 13 years of unfulfilled hopes of investors and the influence of the financial crisis. However, the two renowned investors Polaris and Arch believed in the future of deCODE's business model and pulled the company from the stock market.

According to Fierce Biotech, Polaris and Arch purchased the assets originally for only US-$14m. "deCODE Genetics has built a world-class capability in the study of the genetics of human disease," said Robert Bradway, president and CEO at Amgen. "This capability will enhance our efforts to identify and validate human disease targets. This fits perfectly with our objective to pursue rapid development of relevant molecules that reach the right disease targets while avoiding investments in programs based on less well-validated targets." "One of the ways to truly realise the full value of human genetics, is to make our research synergistic with drug development efforts, where target discovery, validation and prioritisation efforts can be accelerated," said Kari Stefansson, founder and CEO at deCODE Genetics, who will stay with the company.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/from-bargain-to-multi-million-exit.html

ResearchUK

30.01.2015 AstraZeneca has joined forces with four research collaborations to use breakthrough CRISPR gene editing technology across its drug discovery platform.

Stock marketsEU

29.01.2015 Denmark's Ascendis Pharma has successfully raised US$108m with its upsized NASDAQ IPO, while Irish animal health specialist Nexvet is waiting in the wings.

Contract ResearchEU

28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.84 EUR0.00%
  • ACTELION100.80 CHF0.00%
  • ADDEX3.28 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.84 EUR0.00%
  • ACTELION100.80 CHF0.00%

TOP

  • CYTOS0.36 CHF56.5%
  • FORMYCON15.48 EUR53.6%
  • ADDEX3.28 CHF41.4%

FLOP

  • BIOFRONTERA1.93 EUR-16.1%
  • ACTELION100.80 CHF-13.3%
  • MOLOGEN5.75 EUR-9.4%

TOP

  • SANTHERA105.00 CHF2544.8%
  • WILEX1.96 EUR168.5%
  • FORMYCON15.48 EUR103.7%

FLOP

  • CYTOS0.36 CHF-90.1%
  • 4SC0.84 EUR-49.7%
  • MOLOGEN5.75 EUR-49.7%

No liability assumed, Date: 31.01.2015